New arsenal against drug-resistant cancers

New arsenal against drug-resistant cancers

Combining camptothecin, a well-known anticancer alkaloid, with veliparib, an anticancer agent still under clinical trial, researchers have reported good results in treating drug-defying cancers of the breast, ovary, lungs and colon1. The combination therapy kills the cancer cells by inhibiting the activity of two key enzymes that orchestrate DNA replication, protein synthesis and DNA repairRead more about New arsenal against drug-resistant cancers[…]